Treatment of the Psychotic Disorders: Schizophrenia - PowerPoint PPT Presentation

About This Presentation
Title:

Treatment of the Psychotic Disorders: Schizophrenia

Description:

Treatment of the Psychotic Disorders: Schizophrenia Karl Kashfi What is schizophrenia? A mental illness among the world s top ten causes of long-term disability ... – PowerPoint PPT presentation

Number of Views:911
Avg rating:3.0/5.0
Slides: 34
Provided by: facultySm
Learn more at: https://s2.smu.edu
Category:

less

Transcript and Presenter's Notes

Title: Treatment of the Psychotic Disorders: Schizophrenia


1
Treatment of the Psychotic Disorders
Schizophrenia
  • Karl Kashfi

2
What is schizophrenia?
  • A mental illness among the worlds top ten causes
    of long-term disability
  • Develops between the ages of 16 and 30
  • Cause is unknown, but various theories have been
    proposed in regards to a biological cause
  • In addition to biological causes, studies
    indicate a multitude of genetic and environmental
    factors

3
Epidemiology and Prevalence
  • Affects 1 of the population at any one time!
  • Gender-based variations in prevalence of
    schizophrenia (mengtwomen?)
  • Cross-cultural variations in prevalence and the
    nature of the illness?

4
Symptoms
  • The trademark of schizophrenia is an impairment
    in the perception of reality, though there are
    many other symptoms.
  • Three broad types of symptoms
  • Psychotic (positive) symptoms
  • Delusions and hallucinations
  • Negative symptoms
  • Diminution of basic emotional and behavioral
    processes
  • Cognitive impairment
  • Decline in concentration and thinking

5
(No Transcript)
6
Etiology and Risk factors
  • Genetic factors
  • Higher rates of illness among relatives of a
    patient than in general population
  • Environmental factors
  • Prenatal/obstetric complications
  • Brain abnormalities
  • Poverty and low social class (two reasons)
  • Urban residents, migrants, and minorities

7
Onset, Course, and Prognosis
  • Onset of schizophrenia age 16-30 (usually
    earlier in men than in women)
  • Onset lasts 5 years
  • Prodrome
  • Cognitive impairment
  • Psychosis/hospitalization
  • Psychosis is episodic over time negative
    symptoms are more stable
  • No cure less than average life-expectancy

8
Review Neurotransmitters
  • Neurotransmitters are the chemical messengers of
    the nervous system
  • They relay electrical signals from one neuron to
    the next in a series of steps
  • Calcium influx
  • Exocytosis from presynaptic neuron
  • Diffusion across synapse
  • Fusion with postsynaptic neuron and generation of
    impulse
  • Neurotransmitters can be excitatory or inhibitory

9
(No Transcript)
10
Important neurotransmitters
  • Biogenic amines play a role in emotional
    behavior
  • Dopamine
  • Catecholamine (like epinephrine, norepinephrine)
  • Synthesized from amino acid tyrosine
  • Can be inhibitory or excitatory (depends on
    receptor)
  • Feeling good neurotransmitter
  • Seritonin (5-HT)
  • Indolamine
  • Synthesized from amino acid tryptophan
  • Sleep, appetite, mood

11
(No Transcript)
12
History of Drug Discovery
  • 1950s Chlorpromazine found to induce neurolepsy
    in animals and reduce psychosis in psychotic
    patients.
  • These compounds were found to increase metabolism
    of dopamine (less dopamine)
  • Conclusion 1 Good antipsychotic!
  • Conclusion 2 If less dopamine means less
    psychosis, then high dopamine must mean more
    psychosis!

13
Mechanism of Action
  • Inverse relationship found between doses of
    antipsychotics and their affinity for the
    dopamine D2 receptors in the brain.
  • The observations of the 1950s led to the Dopamine
    Hypothesis
  • Excess dopamine leads to psychosis
  • Blockade of postsynaptic D2 receptors should
    provide reversal of psychotic features of
    schizophrenia due to negative feedback reactions.

14
Other Hypotheses
  • If the dopamine hypothesis is true, then blockade
    of D2 receptors by antipsychotics should provide
    immediate reversal of psychosis, BUT this doesnt
    happen.
  • A majority of patients require 2-4 weeks for a
    response
  • Some never even improve appreciably after
    prolonged use of antipsychotics.
  • WHY?
  • Depolarization Inactivation Hypothesis
  • Multiple gene action delay

15
First Generation Antipsychotics
  • The discovery of chlorpromazine set the stage for
    the era of the first-generation antipsychotics
  • Not everyone, however, responded equally
  • 1/3 of patients improved completely, 1/3
    partially, and 1/3 showed little recovery
  • Drug potency inversely related to affinity for
    the D2 receptor sites
  • The dose requirements for 1st generation
    antipsychotics follow a sigmoidal curve relative
    to efficacy.
  • Antipsychotic effects occur in presence of 70
    occupancy of the D2 receptors.

16
  • Chlorpromazine

17
(No Transcript)
18
Side Effects!
  • Severe symptoms are associated with 1st
    generation antipsychotics, known as
    Extrapyramidal Symptoms
  • Dystonias
  • Akathisia
  • Pseudo-Parkinsonian symptoms
  • Unfortunately, therapeutic doses tend to be quite
    close to those which cause EPS
  • Other side effects include prolactin increase and
    tardive dyskinesia.

19
More Problems
  • Another problem with 1st generation
    antipsychotics They suppress positive
    (psychotic) symptoms of schizophrenia, but the
    negative symptoms remain!
  • WHY? Because of NON-SPECIFICITY in dopamine
    receptor blockade.

20
Dopaminergic Neural Pathways
  • Several neural pathways which utilize dopamine
    are located in the midbrain of the brainstem, and
    they mediate such things as emotion,
    fight-or-flight responses, motivation, etc.
  • They are projections from the limbic system
  • These include
  • Mesolimbic pathway
  • Mesocortical pathway
  • Nigrostriatal pathway

21
(No Transcript)
22
(No Transcript)
23
(No Transcript)
24
Motivational salience
  • Mesolimbic dopamine pathways are involved in
    motivational and reward-associated stimuli
  • What is the relationship between these pathways
    and the symptoms of schizophrenia?
  • Motivational salience theory

25
Dopaminergic Neural Pathways
  • Blockage by antipsychotics of dopamine receptors
    in mesolimbic pathway reduction of positive
    (psychotic) symptoms
  • However, antipsychotics also non-specifically
    block the mesocortical and striatal pathways,
    leading to EPS and prolonging of negative
    symptoms.

26
Second generation Antipsychotics
  • Clozapine introduced 1970s
  • 1st of the second generation antipsychotics
  • Second generation antipsychotics atypical
    antipsychotics
  • Atypical because EPS is absent!
  • Other beneficial properties include reduction of
    negative symptoms
  • This is because serotonin receptors are blocked
    as well as dopamine receptors

27
Clozapine Side Effects
  • Clozapine Gold standard in treating
    schizophrenia
  • Has been shown to reduce aggression, substance
    abuse, and treat other mood-related disorders
  • Unfortunately, though very potent, its primary
    problem is agranulocytosis.

28
2nd generation antipsychotics
  • Other 2nd generation antipsychotics exist, which
    work by the same mechanism as clozapine
  • Risperidone
  • Olanzipine
  • Quetiapine
  • Ziprasidone
  • Unfortunately, these also come with side effects,
    which vary with the medication
  • Metabolic disorders (glucose)
  • Weight gain
  • Increased prolactin release

29
(No Transcript)
30
Prognosis of treated patients
  • The success of outcome is a function of the
    promptness of treatment following onset
  • Cognitive function is a relevant parameter in
    prognosis
  • Overall, life expectancy is still shortened when
    compared to the general population due to side
    effects, stigma, and decreased quality of life.
  • Anosognosia!

31
(No Transcript)
32
(No Transcript)
33
What does the future hold?
  • Potentiation techniques
  • D-cycloserine
  • New receptor targets (NMDA receptor)
  • New neurotransmitter systems
  • Dopamine-glutamate
  • Dopamine-acetylcholine
  • Pharmacogenomics
Write a Comment
User Comments (0)
About PowerShow.com